LeuTech gets FDA committee approval

Article

An advisory panel of the FDA last month voted to recommend marketing approval of a Palatin Technologies radiopharmaceutical imaging agent, LeuTech, for diagnosing appendicitis. Officials of the Princeton, NJ, firm said the FDA’s Medical

An advisory panel of the FDA last month voted to recommend marketing approval of a Palatin Technologies radiopharmaceutical imaging agent, LeuTech, for diagnosing appendicitis.

Officials of the Princeton, NJ, firm said the FDA’s Medical Imaging Drugs Advisory Committee determined that LeuTech is safe and effective for use in diagnosing appendicitis in patients with uncertain signs and symptoms of the often life-threatening condition.

The panel’s vote merely suggests approval, but the FDA usually follows the recommendations of its advisory panels, Palatin officials said. The company signed a marketing alliance with St. Louis-based Mallinckrodt last year (SCAN 6/6/99). When LeuTech receives final approval, Mallinckrodt will be in charge of marketing and distributing the radiopharmaceutical. Palatin officials had hoped that LeuTech would be available for sale by the middle of this summer.

The agent binds to white blood cells in vivo, which means that LeuTech can be injected and cells labeled without having to draw blood from the patient (SCAN 5/26/99).

Recent Videos
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Related Content
© 2025 MJH Life Sciences

All rights reserved.